Drag a card by its title · ⚙ to size, swap or remove

Who

Mark J. Enyedy

Director

Company insider

Files Form 4 as: Director, BioMarin Pharmaceutical; Director, Charles River Laboratories International; Chief Executive Officer, ImmunoGen; Director, LogicBio Therapeutics; Director, Akebia Therapeutics; Director, Keryx Biopharmaceuticals; Director, Fate Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed: 84
Buys: 1
Sells: 7
Bought: $46K
Sold: $53.0M
Companies: 7
Companies where not an officer: 6
First trade: 6 Jun 2014
Last trade: 2 Jun 2026
Last filed: 4 Jun 2026

Companies traded

Where they are an officer

ImmunoGenDirector, Officer · last 12 Feb 20241 buy · 7 sells

Everywhere else they filed: board seats, 10% stakes, other companies

BMRN BioMarin PharmaceuticalDirector · Biotechnology · last 2 Jun 20260 buys · 0 sells

CRL Charles River Laboratories InternationalDirector · Life-science tools · last 8 May 20260 buys · 0 sells

LogicBio TherapeuticsDirector · last 16 Nov 20220 buys · 0 sells

AKBA Akebia TherapeuticsDirector · Pharmaceuticals · last 5 Jun 20200 buys · 0 sells

Keryx BiopharmaceuticalsDirector · last 12 Dec 20180 buys · 0 sells

FATE Fate TherapeuticsDirector · Biotechnology · last 2 May 20170 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026

Buys above the line, sells below, each month.

Every trade

Traded	Company	What	Amount
2 Jun 2026filed 4 Jun 2026	BMRN BioMarin PharmaceuticalBiotechnology	SEC FORM 4 Code A	—7,490 at $0.00	filing
2 Jun 2026filed 4 Jun 2026	BMRN BioMarin PharmaceuticalBiotechnology	SEC FORM 4 Code A	—7,490 at $0.00	filing
8 May 2026filed 11 May 2026	CRL Charles River Laboratories InternationalLife-science tools	SEC FORM 4 Code A	$255K1,438 at $177.62	filing
8 May 2026filed 11 May 2026	CRL Charles River Laboratories InternationalLife-science tools	SEC FORM 4 Code A	$255K1,438 at $177.62	filing
2 Jun 2025filed 4 Jun 2025	CRL Charles River Laboratories Internationaloption or derivative · Life-science tools	SEC FORM 4 Code A	$281K2,082 at $135.04	filing
2 Jun 2025filed 4 Jun 2025	CRL Charles River Laboratories InternationalLife-science tools	SEC FORM 4 Code A	$128K946 at $135.04	filing
20 May 2025filed 22 May 2025	BMRN BioMarin PharmaceuticalBiotechnology	SEC FORM 4 Code A	—6,650 at $0.00	filing
21 May 2024filed 23 May 2024	BMRN BioMarin PharmaceuticalBiotechnology	SEC FORM 4 Code A	—4,720 at $0.00	filing
12 Feb 2024filed 12 Feb 2024	ImmunoGenoption or derivative	SEC FORM 4 Code D	—102,466	filing
12 Feb 2024filed 12 Feb 2024	ImmunoGenoption or derivative	SEC FORM 4 Code D	—140,357	filing
12 Feb 2024filed 12 Feb 2024	ImmunoGenoption or derivative	SEC FORM 4 Code D	—196,875	filing
12 Feb 2024filed 12 Feb 2024	ImmunoGenoption or derivative	SEC FORM 4 Code D	—925,000	filing
12 Feb 2024filed 12 Feb 2024	ImmunoGenoption or derivative	SEC FORM 4 Code D	—1,100,000	filing
12 Feb 2024filed 12 Feb 2024	ImmunoGenoption or derivative	SEC FORM 4 Code D	—922,400	filing
12 Feb 2024filed 12 Feb 2024	ImmunoGenoption or derivative	SEC FORM 4 Code D	—1,100,000	filing
12 Feb 2024filed 12 Feb 2024	ImmunoGen	SEC FORM 4 Code D	—584,397	filing
5 Feb 2024filed 6 Feb 2024	ImmunoGen	SEC FORM 4 Sold	$589K20,107 at $29.28	filing
2 Feb 2024filed 6 Feb 2024	ImmunoGenoption or derivative	SEC FORM 4 Code M	—51,234 at $0.00	filing
2 Feb 2024filed 6 Feb 2024	ImmunoGen	SEC FORM 4 Code M	—51,234 at $0.00	filing
1 Feb 2024filed 5 Feb 2024	ImmunoGenoption or derivative	SEC FORM 4 Code A	—140,357 at $0.00	filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed8

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.